Zhilin Li - China Pharma Chairman, CEO and President and Interim CFO
| CPHI Stock | USD 0.20 0.01 5.26% |
Chairman
Ms. Zhilin Li is Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer of China Pharma Holdings, Inc. She has served as a director since 2006 and as the President and Chief Executive Officer since 2005. She was a founder of Helpson, and served as chairman and Chief Executive Officer of Helpson from 1993 to 2005. Ms. Li was formerly the president of Haikou BioEngineering Institute as well as the vice president of Sichuan Institute of Biology. She graduated from Sichuan University with a degree in biology. Her role as a one of the founders of our company and her extensive experience in bioengineering make her well suited to serve as our Chairman. since 2012.
| Age | 71 |
| Tenure | 12 years |
| Phone | 86 89 8668 11730 |
| Web | https://www.chinapharmaholdings.com |
Zhilin Li Latest Insider Activity
Tracking and analyzing the buying and selling activities of Zhilin Li against China Pharma stock is an integral part of due diligence when investing in China Pharma. Zhilin Li insider activity provides valuable insight into whether China Pharma is net buyers or sellers over its current business cycle. Note, China Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell China Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Zhilin Li over a year ago Acquisition by Zhilin Li of 13757063 shares of China Pharma subject to Rule 16b-3 |
China Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1754) % which means that it has lost $0.1754 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7489) %, meaning that it created substantial loss on money invested by shareholders. China Pharma's management efficiency ratios could be used to measure how well China Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 |
China Pharma Holdings Management Team
Elected by the shareholders, the China Pharma's board of directors comprises two types of representatives: China Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of China. The board's role is to monitor China Pharma's management team and ensure that shareholders' interests are well served. China Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, China Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
China Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is China Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (1.50) % | ||||
| Current Valuation | 8.8 M | ||||
| Shares Outstanding | 19.25 M | ||||
| Shares Owned By Insiders | 51.27 % | ||||
| Shares Owned By Institutions | 0.21 % | ||||
| Number Of Shares Shorted | 93.6 K | ||||
| Price To Earning | (0.89) X |
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.